| MeSH term | MeSH ID | Detail |
|---|---|---|
| Dehydration | D003681 | 11 associated lipids |
| Influenza, Human | D007251 | 11 associated lipids |
| Urinary Tract Infections | D014552 | 11 associated lipids |
| Exanthema | D005076 | 11 associated lipids |
| Hyperpigmentation | D017495 | 11 associated lipids |
| Uveitis, Anterior | D014606 | 11 associated lipids |
| Lymphoma, T-Cell | D016399 | 11 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Listeriosis | D008088 | 12 associated lipids |
| Osteoporosis | D010024 | 12 associated lipids |
| Liver Cirrhosis, Biliary | D008105 | 12 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Eye Diseases | D005128 | 12 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
| Hepatitis C, Chronic | D019698 | 12 associated lipids |
| Hypertrophy, Left Ventricular | D017379 | 12 associated lipids |
| Duodenal Ulcer | D004381 | 12 associated lipids |
| Skin Neoplasms | D012878 | 12 associated lipids |
| Keloid | D007627 | 12 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Suzuki H et al. | Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. | 1997 | Transplantation | pmid:9293881 |
| Stevens RB et al. | Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. | 2008 | Transplantation | pmid:18497677 |
| Arns W et al. | Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. | 2017 | Transplantation | pmid:28658202 |
| Yang CW et al. | Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. | 2001 | Transplantation | pmid:11740384 |
| Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
| Jordan ML et al. | Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. | 2000 | Transplantation | pmid:10670637 |
| Hirose R et al. | Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. | 2000 | Transplantation | pmid:10670644 |
| Han DH et al. | Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. | 2010 | Transplantation | pmid:20562737 |
| McGhee B et al. | Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. | 1997 | Transplantation | pmid:9326429 |
| Yoshimura N et al. | The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. | 1994 | Transplantation | pmid:7517078 |
| Budde K et al. | Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. | 2007 | Transplantation | pmid:17318074 |
| Firdaous I et al. | Pediatric intravenous FK506--how much are we really infusing? | 1994 | Transplantation | pmid:7517079 |
| Tuteja S et al. | The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. | 2001 | Transplantation | pmid:11397967 |
| Stifft F et al. | Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. | 2014 | Transplantation | pmid:24686426 |
| Reichenspurner H et al. | Optimization of the immunosuppressive protocol after lung transplantation. | 1999 | Transplantation | pmid:10428269 |
| Pilmore HL et al. | Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. | 2001 | Transplantation | pmid:11726837 |
| Sampaio MS et al. | Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. | 2012 | Transplantation | pmid:22129761 |
| Koenen HJ et al. | Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. | 2003 | Transplantation | pmid:12792519 |
| Jain A et al. | Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. | 2008 | Transplantation | pmid:18347534 |
| Ishizuka J et al. | Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. | 1993 | Transplantation | pmid:7506454 |
| Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
| Robertsen I et al. | Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. | 2015 | Transplantation | pmid:25148382 |
| Kaplan B et al. | Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. | 1999 | Transplantation | pmid:10075604 |
| Gaber AO et al. | Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. | 2008 | Transplantation | pmid:19005398 |
| Erden E et al. | Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. | 1994 | Transplantation | pmid:7519801 |
| Morikawa K et al. | The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. | 1992 | Transplantation | pmid:1281561 |
| McDevitt-Potter LM et al. | A multicenter experience with generic tacrolimus conversion. | 2011 | Transplantation | pmid:21788920 |
| Roth D et al. | Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. | 1998 | Transplantation | pmid:9458023 |
| Gill JS et al. | Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. | 2010 | Transplantation | pmid:20098280 |
| Zhao W et al. | Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. | 2012 | Transplantation | pmid:22450597 |
| Pascual J et al. | Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. | 2009 | Transplantation | pmid:19136902 |
| Ciancio G et al. | A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. | 2005 | Transplantation | pmid:16123718 |
| Berg UB et al. | Renal function before and long after liver transplantation in children. | 2001 | Transplantation | pmid:11544422 |
| Irish W et al. | Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. | 2003 | Transplantation | pmid:14688516 |
| Gruessner RW et al. | Mycophenolate mofetil in pancreas transplantation. | 1998 | Transplantation | pmid:9721799 |
| Emond JC et al. | Improved results of living-related liver transplantation with routine application in a pediatric program. | 1993 | Transplantation | pmid:7682738 |
| Chisholm MA et al. | Coadministration of tacrolimus with anti-acid drugs. | 2003 | Transplantation | pmid:12973105 |
| Kershner RP and Fitzsimmons WE | Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. | 1996 | Transplantation | pmid:8878385 |
| Devlin J et al. | Nitric oxide generation. A predictive parameter of acute allograft rejection. | 1994 | Transplantation | pmid:7522365 |
| Jordan ML et al. | Tacrolimus rescue therapy for renal allograft rejection--five-year experience. | 1997 | Transplantation | pmid:9020321 |
| Higgins R et al. | Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. | 2009 | Transplantation | pmid:19300192 |
| Steiner RW | Steroid withdrawal in kidney transplantation: the subgroup fallacy. | 2011 | Transplantation | pmid:21336084 |
| Dhar DK et al. | The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. | 1992 | Transplantation | pmid:1384188 |
| Bashuda H et al. | Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. | 1996 | Transplantation | pmid:8693525 |
| Hughes JR et al. | Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. | 1999 | Transplantation | pmid:10480422 |
| Cacciarelli TV et al. | Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1998 | Transplantation | pmid:9808490 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. | 2005 | Transplantation | pmid:15729180 |
| Griffith BP et al. | A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. | 1994 | Transplantation | pmid:7512292 |
| Sun S et al. | Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. | 1996 | Transplantation | pmid:8633368 |
| Kashu Y et al. | The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. | 1996 | Transplantation | pmid:8633382 |